Intratumoral Interleukin-2 Injections Without Systemic Therapy for Isolated Cutaneous Metastatic Breast Cancer

Gorman, Benjamin G.; Jakub, James W.; Hobday, Timothy J.; Brewer, Jerry D.

doi:10.1097/dss.0000000000003050

Cited by 1 publication

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Together, this data illustrates imiquimod may have a favorable use in this setting. Intralesional IL-2, on the other hand, has not widely been used in cutaneous metastatic breast cancer, outside of a recent case report in 2021 ( 7 ). Certainly, in our patient, intralesional IL-2 monotherapy was able to generate a partial response initially.…”

Section: Discussionmentioning

confidence: 99%

“…Intralesional interleukin-2 (IL-2) injections have been used successfully to treat cutaneous metastases in other cancers, including melanoma ( 5 ) and porocarcinoma ( 6 ). However, the use of IL-2 in the treatment of breast cancer is not well-described, with a single case study published in 2021 reporting a pathologic complete response after intralesional IL-2 injections in a patient with triple-negative breast cutaneous cancer metastasis ( 7 ). Few others have had some success in treating cutaneous metastatic breast cancer with imiquimod, a topical Toll-like receptor 7 (TLR7) agonist ( 8 – 10 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cutaneous Breast Cancer Metastasis Is Effectively Treated With Intralesional Interleukin-2 and Imiquimod: A Case Report and Brief Literature Review

et al. 2022

View full text Add to dashboard Cite

Breast cancer is the most common non-cutaneous cancer affecting women worldwide and is a major cause of cancer-related morbidity and mortality in females. While many women are diagnosed with early-stage disease, a subset of women may present with isolated cutaneous metastases or recurrent locoregional cutaneous metastatic disease. There is a paucity of evidence for effective treatments for cutaneous breast cancer metastases. Herein, we present a case of hormone receptor negative, HER2 positive cutaneous breast cancer metastasis treated with intralesional IL-2 and topical imiquimod, which was well tolerated with only minor low grade side effects. We also present a brief literature review of immunotherapy for cutaneous breast cancer metastasis to frame the discussion around using minimally invasive local therapies for this disease. Together, this limited data suggests that intralesional IL-2 and imiquimod may be considered as a safe option when treating a patient with cutaneous breast cancer metastases.

show abstract

Section: Discussionmentioning

confidence: 99%